Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-08-08
2006-08-08
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S543000, C562S426000
Reexamination Certificate
active
07087645
ABSTRACT:
The use of compounds of the formulaand pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.
REFERENCES:
patent: 3179701 (1965-04-01), Rocklin
patent: 3479407 (1969-11-01), Laufer
patent: 3576883 (1971-04-01), Neuworth
patent: 3952064 (1976-04-01), Whalley
patent: 4029812 (1977-06-01), Wagner
patent: 4076841 (1978-02-01), Wagner
patent: 4078084 (1978-03-01), Wagner
patent: 4115590 (1978-09-01), Lerner
patent: 4752616 (1988-06-01), Hall
patent: 4755524 (1988-07-01), Mueller et al.
patent: 4954514 (1990-09-01), Kita
patent: 4968710 (1990-11-01), Rustad
patent: 4975467 (1990-12-01), Ku et al.
patent: 5043330 (1991-08-01), Nguyen et al.
patent: 5061734 (1991-10-01), Mao et al.
patent: 5066822 (1991-11-01), Rustad et al.
patent: 5084214 (1992-01-01), Kita et al.
patent: 5112870 (1992-05-01), Mao et al.
patent: 5155250 (1992-10-01), Parker
patent: 5206247 (1993-04-01), Regnier
patent: 5262439 (1993-11-01), Parthasarathy
patent: 5294430 (1994-03-01), Borch et al.
patent: 5294724 (1994-03-01), Jendralla et al.
patent: 5310949 (1994-05-01), Dufresne et al.
patent: 5380747 (1995-01-01), Medford
patent: 5411741 (1995-05-01), Azias
patent: 5426196 (1995-06-01), Fang et al.
patent: 5512595 (1996-04-01), Regnier et al.
patent: 5608095 (1997-03-01), Parker
patent: 5627205 (1997-05-01), Regnier et al.
patent: 5693337 (1997-12-01), Suzuki et al.
patent: 5739374 (1998-04-01), Janssen et al.
patent: 5750351 (1998-05-01), Medford
patent: 5770355 (1998-06-01), Brocia
patent: 5773209 (1998-06-01), Medford et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5783596 (1998-07-01), Medford et al.
patent: 5792787 (1998-08-01), Medford et al.
patent: 5807884 (1998-09-01), Medford et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5821260 (1998-10-01), Medford et al.
patent: 5846959 (1998-12-01), Medford et al.
patent: 6037377 (2000-03-01), Anderskewitz et al.
patent: 6121319 (2000-09-01), Somers
patent: 6147250 (2000-11-01), Somers
patent: 6323359 (2001-11-01), Jass
patent: 6448019 (2002-09-01), Mendelsohn et al.
patent: 6548699 (2003-04-01), Somers
patent: 6602914 (2003-08-01), Meng
patent: 6617352 (2003-09-01), Somers
patent: 6670398 (2003-12-01), Edwards et al.
patent: 2002/0188118 (2002-12-01), Meng
patent: 2002/0193446 (2002-12-01), Meng
patent: 2003/0064967 (2003-04-01), Luchoomun et al.
patent: 27 16 125 (1977-10-01), None
patent: 0190682 (1986-08-01), None
patent: 0212310 (1987-03-01), None
patent: 0254272 (1988-01-01), None
patent: 0292660 (1988-11-01), None
patent: 0317165 (1989-05-01), None
patent: 0348203 (1989-12-01), None
patent: 0405788 (1991-01-01), None
patent: 0418648 (1991-03-01), None
patent: 0621255 (1994-10-01), None
patent: 0763527 (1997-03-01), None
patent: 0866049 (1998-09-01), None
patent: 2130975 (1972-11-01), None
patent: 2133024 (1972-11-01), None
patent: 2134810 (1972-12-01), None
patent: 2140769 (1973-01-01), None
patent: 2140771 (1973-01-01), None
patent: 2168137 (1973-08-01), None
patent: 1136539 (1968-12-01), None
patent: 1148550 (1969-04-01), None
patent: 1199871 (1970-07-01), None
patent: 49-075552 (1974-07-01), None
patent: 06-312978 (1994-11-01), None
patent: 73-28425 (1995-12-01), None
patent: 09-059258 (1997-03-01), None
patent: WO 93/02051 (1993-02-01), None
patent: WO 94/07869 (1994-04-01), None
patent: WO 95/09158 (1995-04-01), None
patent: WO 95/15760 (1995-06-01), None
patent: WO 95/17408 (1995-06-01), None
patent: WO 95/30415 (1995-11-01), None
patent: WO 96/12703 (1996-05-01), None
patent: WO 97/15546 (1997-05-01), None
patent: WO 97/26258 (1997-07-01), None
patent: WO 97/48694 (1997-12-01), None
patent: WO 98/22418 (1998-05-01), None
patent: WO 98/30255 (1998-07-01), None
patent: WO 98/42327 (1998-10-01), None
patent: WO 98/51289 (1998-11-01), None
patent: WO 98/51662 (1998-11-01), None
patent: WO 99/15159 (1999-04-01), None
patent: WO 99/24400 (1999-05-01), None
patent: WO 00/26167 (2000-05-01), None
patent: WO 00/26184 (2000-05-01), None
patent: WO 00/28332 (2000-05-01), None
patent: WO 00/31053 (2000-06-01), None
patent: WO 00/53795 (2000-09-01), None
patent: WO 00/59509 (2000-10-01), None
patent: WO 01/70757 (2001-09-01), None
patent: WO 01/70757 (2001-09-01), None
patent: WO 01/79164 (2001-10-01), None
patent: WO 01/79164 (2001-10-01), None
Anonymous, “AtheroGenics announces positive Phase II results from CART-1 Clinical Trial for restenosis,” (Press Release Nov. 12, 2001).
Anonymous, “AtheroGenics: Faster than anticipated,”BioCentury Extra(The Bernstein Report of Biobusiness), Reprint from May 29, 2001.
Barnhart, J.W., et al., Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs,Pharmacochem. Libr.,1991(17):277-299 (1991). XP002095165.
Baron, J.L., et al., “The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between α-4-integrins and vascular cell adhesion molecule-1”,J. Clin. Invest. 93:1700-1708 (Apr. 1994).
Brown, et al., “Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis”,Ann. Rev. Biochem., 52:223-261 (1983).
Burkly, L.C., et al., “Protection against adoptive transfer of autoimmune diabletes mediated through very late antigen-4 integrin”,Diabetes, 43:529-534 (Apr. 1994).
Carew, et al., “Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidantsin vivocan selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit”,Proc. Natl. Acad. Sci. U.S.A., 84:7725-7729 (Nov. 1987).
Cominacini, L., et al.,Free Radical Biology and Medicine, 22(1/2):117-127 (1996) XP002095164.
De Meglio, P., “New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity,”II Farmaco, Ed. Sci. 40(11):833-844 (1985).With partial translation. Chem. Abstracts, 104(5):28675, (Feb. 3, 1986), XP 002124424.
Feldman, D., et al., “The In Vitro and Ex Vivo Antioxidant Properties, and Hypolipidemic Activity of CGP 2881,”Atherosclerosis, 144:343-355 (Dec. 28, 1998).
Folkman, J., et al., “Angiogenesis”,J. Biol. Chem., 267(16):10931-10934 (Jun. 5, 1992).
Fruebis, J., “A Comparison of the Antiatherogenic Effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits,”The American Society for Clinical Investigation, Inc., 94:392-398 (Jul. 1994).
Gershbein et al., “Action of drugs and chemical agents on rat liver regeneration,”Drug and Chemical Toxicology, 8(3):125-143 (1985).
Heeg, et al., “Plasma levels of Probucol in man after single and repeated oral doses”,La Nouvelle Presse Medicale, 9(40):2990-2994 (Oct. 30, 1980). Abstract in English.
Iademarco, M.F., et al., “Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1)”,J. Biol. Chem. 267(23):16323-16329 (Aug. 15, 1992).
Kazuya et al.,J. Lipid Res., 32:197-204 (1991).
Kelarev, V.I., et al.,Khim. Geterotsikl. Soedin, No. 5, pp. 667-673 (1995). Provided asChem. Abstracts, AN 124:146082, XP002115604.
Kelarev, V.I., et al.,Khim. Geterotsikl. Soedin., No. 4, pp. 514-517 (1995). Provided asChem. AbstractsAN 124(1):8690 (Jan. 1, 1996) XP002115603 and XP002115596.
Koch, A.E., et al., “Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues”,Lab. Invest., 64(3):313-320 (1991).
Lankin, V.Z., et al.,Dokl. Akad. Nauk.,351(4):554-557 (1996),Chem. Abstracts, AN 127(6):75973u (1997), XP002115597.
Mamedov, Ch.I., et al.,Mater. Nauchn. Konf. Aspir. Akad. Nauk Az. SSR, 1:127-131 (1980),Chem, Abstracts, AN 94:30290c (1981), XP002115600.
Mao., S.J., et al., “Antioxidant Activity of Probucol and Its Analogues in Hypercholesterolemic watanabe Rabbits,”Journal of Medicin
Edwards David B.
Glass Mitchell
Somers Patricia K.
AtheroGenics, Inc.
Davis Zinna N.
King & Spalding LLP
Knowles, Esq. Sherry
LandOfFree
Compounds and methods for treating transplant rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treating transplant rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treating transplant rejection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3687767